|Articles|May 1, 1996

May 1996
Volume 2
Issue 5

Any Willing IPA: Shaping the Market Through Legislation

Download PDF: Any Willing IPA: Shaping the Market Through Legislation

Articles in this issue

about 30 years ago

Article

Correspondence regarding, "Intended and Unintended Consequences of HMO Cost-Containment Strategies: Results from the Managed Care Outcomes Project"

about 30 years ago

Article

Correspondence regarding, "Intended and Unintended Consequences of HMO Cost-Containment Strategies: Results from the Managed Care Outcomes Project"

about 30 years ago

Article

about 30 years ago

Article

The Professionalism of Pharmacy in a Managed Care Setting

about 30 years ago

Article

The Unique Application of Telemedicine to the Managed Healthcare System

about 30 years ago

Article

Management of the Menopausal Woman

about 30 years ago

Article

Using Administrative Data and a Diagnosis Clustering Program to Assess Healthcare Needs of African Americans

about 30 years ago

Article

The Relationship Between Borderline Personality Symptomatology and Healthcare Utilization Among Women in an HMO Setting

about 30 years ago

Article

Assessing the Real-Life Relationship Between Average Capillary Blood Glucose and Hemoglobin A1C: Is the Average Capillary Blood Glucose Value Clinically Useful?

about 30 years ago

Article

Health Care Credentialing and Qualifications Commission: An Alternative to "Any Willing Provider"?

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe

Related Content

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

ByEmily A. Gadbois, PhD,Jennifer Bunker, MPH,Marguerite Daus, PhD, RN,Jamie M. Smith, PhD, RN,Emily Buss, MSN, RN,Christine D. Jones, MD, MS,Kali S. Thomas, PhD, MA

July 16th 2026

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

ByHeather L. Taylor, MPH, LDH,Ann M. Holmes, PhD,Nir Menachemi, PhD, MPH,Justin Blackburn, PhD

July 10th 2026

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

ByChristopher Scannell, MD, PhD,John A. Romley, PhD,Rebecca Myerson, PhD,Dana Goldman, PhD,Dima Mazen Qato, PharmD, PhD, MPH

July 9th 2026

Upper Payment Limit Implementation Risks for Patients, Pharmacies, and Providers

ByJulie A. Patterson, PharmD, PhD,Roswell A. Cole, PharmD, MPH,Jonathan D. Campbell, PhD, MS,John Michael O’Brien, PharmD, MPH

July 9th 2026

The New Oncology Blueprint: Integrating Clinical Intelligence for Sustainable Value

ByVivian T. E. Tar, PharmD, MBA

July 8th 2026

Any Willing IPA: Shaping the Market Through Legislation

Articles in this issue

Related Content

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

Upper Payment Limit Implementation Risks for Patients, Pharmacies, and Providers

The New Oncology Blueprint: Integrating Clinical Intelligence for Sustainable Value

Trending on AJMC

FDA Approves Enlicitide, First Oral PCSK9 for High Cholesterol

Cardiology Prices Vary Widely by Insurer and State

Medicaid MFN Pricing Could Save $8.6 Billion

CRC Treatment Delays Linked to Higher Metastasis Risk, Supporting Pathway-Specific Benchmarks

Hepatitis Prevention Programs Improve Liver Outcomes, but Gaps in Screening, Care Remain